NBP's Chief Medical Officer Sells Shares

Dennis Phillip Andrew, the Chief Medical Officer of NBP, sold 8,494 shares of the company on June 18, 2026. The shares were sold at an average price of $0.66 each, totaling $5,606.04. This transaction was not part of a pre-scheduled trading plan.

Insider Buying and Selling at NovaBridge Biosciences

In addition to Andrew's recent sale, he also sold 10,302 shares on June 17, 2026. However, he purchased 23,695 shares on the same day, indicating a mix of buying and selling activity. Another insider, Xu Cong Claire, who is the Senior Vice President of Clinical Development, sold 3,494 shares at $3.94 on June 1, 2026, while buying 9,382 shares on May 30, 2026.

Other Institutional Activity in NBP

Several institutional investors have been adjusting their positions in NBP. Janus Henderson Group PLC reduced its holdings by 2,403,991 shares, bringing its total to 6,032,650 shares worth about $14.81 million. HHLR Advisors, Ltd. maintained its position with 5,980,568 shares valued at $14.71 million. Morgan Stanley increased its stake slightly by 52,696 shares, ending with 3,838,198 shares valued at $9.44 million. Meanwhile, AIHC Capital Management Ltd significantly boosted its holdings by 1,848,954 shares, totaling 2,262,933 shares worth approximately $5.57 million.

Analysts Set New Price Targets

On February 6, 2026, HC Wainwright & Co. maintained its 'buy' rating for NBP, setting a price target of $9.00.

Bottom Line

Insider transactions, such as those by Dennis Phillip Andrew, are closely watched by investors for insights into company prospects. Andrew's recent sales and purchases reflect active trading in NBP's stock. Institutional movements, including Janus Henderson Group's notable reduction, also play a role in shaping market perceptions. As always, these filings provide a backward-looking snapshot and may not reflect current positions.